# Efficacy and Safety of RZL-012 on Submental Fat Reduction

> **NCT04867434** · PHASE2 · COMPLETED · sponsor: **Raziel Therapeutics Ltd.** · enrollment: 151 (actual)

## Conditions studied

- Submental Fat

## Interventions

- **DRUG:** RZL-012
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04867434
- **Lead sponsor:** Raziel Therapeutics Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-06-15
- **Primary completion:** 2022-04-20
- **Final completion:** 2022-05-31
- **Target enrollment:** 151 (ACTUAL)
- **Last updated:** 2023-09-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04867434

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04867434, "Efficacy and Safety of RZL-012 on Submental Fat Reduction". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04867434. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*